Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
No quarterly figures reported.
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $361.5K3 | $641.6K3 | $345.0K4 | $255.4K4 | $243.5K5 | $217.6K5 | ||
| Selling, general and admin | $2.8M3 | $2.2M3 | $1.8M4 | $907.8K4 | $593.5K5 | $1.0M5 | ||
| Operating income | -$3.1M3 | -$2.8M3 | -$2.1M4 | -$513.2K4 | -$837.0K5 | -$1.3M5 | ||
| Interest | $82.6K3 | $172.8K3 | $20.2K4 | $39.5K4 | $43.8K5 | $57.4K5 | ||
| Income tax | -$1.5M3 | -$305.7K3 | $05 | $05 | $05 | $05 | ||
| Net income | -$3.7M3 | -$2.9M3 | -$1.9M4 | -$434.9K4 | $866.7K5 | -$517.9K5 | ||
| Earnings per share | -$0.134 | -$0.034 | $0.054 | |||||
| Earnings per share (diluted) | -$0.134 | -$0.034 | $0.054 |
No quarterly figures reported.
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Cash | $21.5K3 | $930.4K3 | $4005 | $386.0K5 | ||||
| Current assets | $30.8K3 | $940.8K3 | $74.0K4 | $101.1K4 | $32.8K5 | $410.6K5 | ||
| Total assets | $37.3K3 | $1.1M3 | $209.8K4 | $161.9K4 | $35.4K5 | $567.0K5 | ||
| Current liabilities | $3.8M3 | $4.4M3 | $5.4M4 | $5.8M4 | $4.8M5 | $5.0M5 | ||
| Total liabilities | $3.8M3 | $4.4M3 | $5.4M4 | $5.8M4 | $4.9M5 | $5.1M5 | ||
| Shareholders’ equity | -$3.8M6 | -$3.1M3 | -$4.8M4 | -$5.2M4 | -$4.3M5 | -$3.9M5 | ||
| Shares outstanding | 13.2M shares3 | 13.7M shares3 | 14.4M shares4 | 14.4M shares4 | 14.5M shares5 | 40.3M shares5 | 49.6M shares4 | 64.9M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Corporate structure
Gene Biotherapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Gene Biotherapeutics, Inc.
- Christopher J. Jemapete Filed SC 13G/A on Gene Biotherapeutics, Inc., latest Feb 3, 2023
- SABBY MANAGEMENT, LLC Filed SC 13G/A on Gene Biotherapeutics, Inc., latest Jan 5, 2022
- Gene Biotherapeutics, Inc. San Diego, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Gene Biotherapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $207.0K5 Dec 31, 2020 | $203.6K5 Dec 31, 2019 | +1.7% |
| Accumulated depreciation | $202.8K5 Dec 31, 2020 | $201.0K5 Dec 31, 2019 | +0.9% |
| Property and equipment, net | $4.3K5 Dec 31, 2020 | $2.6K5 Dec 31, 2019 | +61.1% |
| Operating-lease assets (leased space) | $145.0K5 Dec 31, 2020 |
Real estate and locations
| Item | Latest | A year before | Change |
|---|---|---|---|
| Area of land | 3,039 sq ft5 Aug 2, 2020 |
Investments
Leadership
Who has led Gene Biotherapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
President
Chief financial officer
Chief operating officer
- Chief executive officerChristopher J. Reinhard Nov 12, 2008 to Mar 27, 20157
- ChairJames L. Grainer Aug 14, 2020 to Aug 14, 20208
- PresidentMichael Magers Apr 13, 2007 to Nov 2, 20079
- Chief financial officerJames L. Grainer Aug 14, 2020 to Aug 14, 20208
- Chief financial officerDennis Mulroy Mar 17, 2009 to Mar 4, 201410
- Chief operating officerMichael Magers Apr 13, 2007 to Nov 2, 20079
Board members and other officers (13)
- Chief Scientific OfficerRonald J. Shebuski Jul 8, 2020 to Jul 8, 202011
- Chief Business OfficerTyler Michael Dylan Nov 12, 2008 to Mar 4, 201412
- Exec VP and Chief Med OfficerRandall Moreadith Jan 26, 2006 to Jan 26, 200613
- Chief Scientific OfficerGabor M. Rubanyi Jun 9, 2006 to Mar 4, 201414
- Board memberKaushik K. Vyas Jul 8, 2020 to Jul 8, 202015
- Board memberChristopher J. Reinhard Nov 12, 2008 to Mar 27, 20157
- Board memberTyler Michael Dylan Nov 12, 2008 to Mar 4, 201412
- Board memberAndrew M. Leitch Aug 24, 2007 to Mar 27, 201516
- Board memberEdward W. Gabrielson Jan 26, 2006 to Mar 27, 201517
- Board memberGerald J. Lewis Jan 26, 2006 to Mar 27, 201518
- Board memberLon E. Otremba Jan 26, 2006 to Mar 27, 201519
- Board memberMurray H. Hutchison Jan 26, 2006 to Mar 27, 201520
- Board memberRonald I. Simon Jan 26, 2006 to Jan 26, 200621
Former names
Timeline
- Nov 12, 2008New chief executive Christopher J. Reinhard becomes CEO7
Filings
6 filings to the SEC since October 2021: 2 annual reports, 1 quarterly reports, 2 large holders, 1 other. The latest 6:
- Oct 15, 2024REVOKED EDGAR
- Feb 3, 2023SC 13G/A EDGAR
- Apr 14, 202210-K/A EDGAR
- Mar 30, 202210-K EDGAR
- Jan 5, 2022SC 13G/A SABBY 13G-A CRXM 1.04.22 EDGAR
- Oct 27, 202110-Q EDGAR
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Christopher J. JemapeteSC 13G/A, 1 filing Feb 3, 202322
- SABBY MANAGEMENT, LLCSC 13G/A, 1 filing Jan 5, 202223
SEC filer profile
How Gene Biotherapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARGene Biotherapeutics, Inc.1
- CIK0000772320
- Employer ID (EIN)84-06356731
- Filer statusNon-accelerated filer<br>smaller reporting company1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address11750 Sorrento Valley Road, Suite 250, San Diego, CA 921211
- Phone(858) 436-10001
- Shares outstanding64,931,888 as of Mar 15, 20225
- Public float$1.1M as of Jun 30, 20215
- On EDGAR sinceMay 15, 19961
- Filings546 in all: 8-K (193), 4 (47), 10-Q (44), 10QSB (22), 3 (22), 10-K (15), NT 10-Q (14), SC 13D (14)1
All 49 form types
CORRESP (13), 424B5 (12), SC 13D/A (12), DEF 14A (11), NT 10-K (11), 8-K/A (10), UPLOAD (10), 10KSB (9), 10QSB/A (9), SC 13G/A (8), S-3 (7), REGDEX (6), S-3/A (6), EFFECT (5), PRE 14A (4), S-8 (4), DEFA14A (3), POS AM (3), SC 13G (3), 10-K/A (2), 10-K405/A (2), 10-Q/A (2), 424B3 (2), S-1/A (2), S-8 POS (2), SC TO-I/A (2), 10KSB/A (1), 25 (1), 8-A12B (1), 8-A12G (1), CERTAMX (1), D (1), DEF 14C (1), PRER14A (1), REGDEX/A (1), REVOKED (1), RW (1), S-1 (1), SB-2 (1), SB-2/A (1), SC TO-I (1)
- Latest filingsAnnual report (10-K) Mar 30, 2022
Quarterly report (10-Q) Oct 27, 2021
Proxy statement (DEF 14A) May 28, 2015
Latest 8-K (8-K) Aug 5, 2021
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARJames L. Grainer, Chair
- 9SEC EDGARMichael Magers, President
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARKaushik K. Vyas, Board member
- 16SEC EDGARAndrew M. Leitch, Board member
- 17SEC EDGAREdward W. Gabrielson, Board member
- 18SEC EDGARGerald J. Lewis, Board member
- 19SEC EDGARLon E. Otremba, Board member
- 20SEC EDGARMurray H. Hutchison, Board member
- 21SEC EDGARRonald I. Simon, Board member
- 22
- 23